title: Inhibition of the HIV Rev transactivator : a new target for therapeutic intervention.
abstract: The viral transactivator Rev is essential for HIV replication, since it allows the nuclear export of unspliced and partially spliced viral mRNAs that encode the structural proteins. Rev is an RNA binding protein that interacts with a highly structured RNA element, the RRE, found within the envelope sequences. This viral protein also interacts with cellular proteins, termed nucleoporins, and acts as an adaptor between the viral mRNAs and the cellular nuclear export machinery. Both interactions are specific, and required for Rev function. Because of its crucial role in the HIV replication cycle, and its novel mechanism of action, Rev represents an ideal target for therapeutic intervention. This review describes the efforts towards Rev inhibition. Gene therapy approaches, including the expression of trans-dominant mutants and RNA decoys, as well as antisense therapies and small molecule inhibitors of Rev-RRE binding or Rev interaction with the cellular machinery will be discussed
authors.affiliation: Oncogene Science, Inc., 106 Charles Lindbergh Blvd., Uniondale, NY 11553, USA. aheguy@oncogene.com
authors.forename: A
authors.initials: A
authors.lastname: Heguy
mesh_terms: D015694:Gene Products, rev / Q000235:genetics* / Q000502:physiology*; D015316:Genetic Therapy; D015658:HIV Infections / Q000235:genetics / Q000628:therapy; D006801:Humans; D014779:Virus Replication; D054321:rev Gene Products, Human Immunodeficiency Virus
chemical_list: D015694:Gene Products, rev; D054321:rev Gene Products, Human Immunodeficiency Virus